Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical CoKYRNF 70 Earnings Yield (Joel Greenblatt) % is 4.56% as of Mar. 2026, which is 39% below its 10-year median of 7.49. GuruFocus rates KYRNF with a GF Score™ of 70/100 and a GF Value™ of $14.06. The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks better than 56.7% on this metric.
Kyorin Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $647.1 Mil.
Kyorin Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $19.9 Mil. Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 4.56%.
The historical rank and industry rank for Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
KYRNF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.34 Med: 7.49 Max: 19.84
Current: 4.34
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Kyorin Pharmaceutical Co was 19.84%. The lowest was 4.34%. And the median was 7.49%.
KYRNF's Earnings Yield (Joel Greenblatt) % is ranked better than 56.7% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.25
vs KYRNF: 4.34
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Kyorin Pharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.82%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Kyorin Pharmaceutical Co (OTCPK:KYRNF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Kyorin Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Related Terms
Kyorin Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart
KYRNF vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % falls into.
Kyorin Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Kyorin Pharmaceutical Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Kyorin Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.9 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 4.56% mean?
Kyorin Pharmaceutical Co (KYRNF) has a Earnings Yield (Joel Greenblatt) % of 4.56% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Kyorin Pharmaceutical Co and its competitors. This is 39% below median its historical median of 7.49. Over the past decade, Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % has ranged from 4.34 to 19.84. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #436 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 43.3%.
Is Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % too high?
Kyorin Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 4.56% is 39% below median its 10-year median of 7.49. Over the past 10 years, this metric has ranged from a low of 4.34 to a high of 19.84. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.25. Kyorin Pharmaceutical Co's value of 4.56% is 40.3% above this industry median. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #436 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #436 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This puts Kyorin Pharmaceutical Co in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.25. Kyorin Pharmaceutical Co's value of 4.56% is 40.3% above this benchmark. Historically, Kyorin Pharmaceutical Co's own Earnings Yield (Joel Greenblatt) % has ranged from 4.34 to 19.84 over the past decade. While the company's 10-year median is 7.49 vs. the industry median of 3.25, Kyorin Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.25, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyorin Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 4.56% is 40.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Kyorin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % is 4.56%, which is 39% below median its own 10-year median of 7.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Kyorin Pharmaceutical Co (KYRNF) has a current Earnings Yield (Joel Greenblatt) % of 4.56%. The stock's GF Value™ is $14.06, compared to a current price of $10.31 — trading 26.7% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 4.56%, which is 39% below median its 10-year median of 7.49 and 40.3% above the Drug Manufacturers industry median of 3.25. Kyorin Pharmaceutical Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (KYRNF), the current Earnings Yield (Joel Greenblatt) % is 4.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (KYRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of $10.31 is trading 26.7% below its estimated GF Value™ of $14.06.
Key valuation signals for KYRNF:
Earnings Yield (Joel Greenblatt) %: 4.56% (39% below median its 10-year median of 7.49)
GF Value™: $14.06 vs. price of $10.31 (26.7% below fair value)
Industry Position: 40.3% above the Drug Manufacturers median (#436 of 1007)
No single metric tells the full story. See the KYRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
70GF Score
Get the complete analysis for KYRNF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYRNF has been successfully added to your 
